Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

NCT01618214 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: biphasic insulin aspart 30

Sponsor

Novo Nordisk A/S